CareDx (CDNA) vs GRAIL (GRAL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CareDx (CDNA) has outperformed GRAIL (GRAL) over the past year, gaining 329.7% versus a gain of 111.6%. GRAIL is the larger company by market cap ($5.80 billion vs $3.24 billion), about 1.8 times the size. CareDx converts more of its revenue into profit, with a net margin of -5.6% versus -277.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDNA | GRAL |
|---|---|---|
| Share price | $62.60 | $129.82 |
| Market cap | $3.24B | $5.80B |
| 1-day change | -0.70% | -2.32% |
| YTD return | +234.61% | +55.28% |
| 1-year return | +329.72% | +111.56% |
| 5-year return | -11.21% | — |
| P/E ratio (TTM) | 30.10 | — |
| Forward P/E | 48.53 | — |
| EPS (TTM) | $2.08 | $-9.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $379.81M | $147.17M |
| Revenue growth (YoY) | +13.79% | +17.18% |
| Net income (latest FY) | $-21.35M | $-408.35M |
| Operating margin | -8.10% | -381.98% |
| Net margin | -5.62% | -277.47% |
| 52-week high | $72.51 | $166.48 |
| 52-week low | $13.95 | $41.50 |
| Distance from 52-week high | -13.67% | -22.02% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.02% | -13.42% |
| Average volume | 1.28M | 931.73K |
| Shares outstanding | 51.73M | 44.67M |
| Employees | 761 | 910 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDNA has outperformed GRAL by 218.2 percentage points over the past year.
- CareDx is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -277.5 cents for GRAIL.
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
About GRAIL
GRAL stock →GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Health Care · Medical Specialities · 910 employees
CDNA vs GRAL FAQ
Which is bigger, CareDx or GRAIL?
GRAIL (GRAL) is larger, with a market capitalization of $5.80B compared with $3.24B for CareDx (CDNA).
Which stock has performed better over the past year, CDNA or GRAL?
CDNA returned +329.72% over the past 12 months, compared with +111.56% for GRAL (price return, excluding dividends). Past performance does not predict future results.
Are CareDx and GRAIL in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.